The five-year survival curves for women with metastatic cancer and molecular typing show that a triple-negative molecular profile (HER2−/HR−) was associated with the worst survival, while the best survival was seen in women with HER2−/HR+ or HER2+/HR+ tumors (Figure 5). Here, ERBB2 is linked to metastatic malignant neoplasm.